INTRODUCTION
The cardiac variant of Fabry disease is associated with significant morbidity and early death. We report the case of a 60-year-old man who was admitted with severe dyspnea at rest. He developed heart failure with severe left ventricular (LV) systolic dysfunction, sustained atrial flutter, and frequent nonsustained ventricular tachycardia. He was diagnosed with the cardiac variant of Fabry disease and was treated with flutter ablation, optimal medical therapy, and cardiac resynchronization therapy (CRT) with a defibrillator. Three years after CRT, he is totally asymptomatic and is able to perform activities of daily living and work with no limitations. This report highlights the role of advanced echocardiography to evaluate LV function in patients with the cardiac variant of Fabry disease.
We previously reported a case of cardiac variant of Fabry disease treated with CRT. 1 Three years of follow-up on this rare case will be detailed, as excellent images were successfully recorded along with the clinical course. This report highlights the role of advanced echocardiography to evaluate LV function in patients with cardiac variant of Fabry disease.
CASE PRESENTATION
A 60-year-old man who had received a diagnosis of hypertrophic cardiomyopathy 13 years previously ( Figure 1 ) was admitted to our hospital with severe dyspnea at rest (New York Heart Association class IV). He had developed heart failure with severe LV systolic dysfunction with an LV ejection fraction of 20% (Videos 1 and 2), sustained atrial flutter (Figure 2 ), and frequent nonsustained ventricular tachycardia. Dyssynchrony in the left ventricle was observed as a time delay of 164 msec between Tc-tetrofosmin at the posterior wall (arrows).
endomyocardial biopsy, as there were no clinical signs of ocular, renal, or skin involvement. Single-photon emission computed tomography showed poor perfusion in the posterior wall of the left ventricle ( Figure 4 ). On cardiac magnetic resonance imaging, a late-enhanced signal after gadolinium infusion was observed in the same lesion. 1 After treatment of acute heart failure with optimal medication (spironolactone 25 mg, furosemide 20 mg, carvedilol 15 mg, candesartan 4 mg, and warfarin 3 mg), enzyme replacement therapy with agalsidase-b at 1 mg/kg every other week was instituted. Three years after CRT, echocardiography revealed improved LV wall motion (Videos 3 and 4), and no significant LV dyssynchrony (Figure 3, right) was observed. Meanwhile, peak systolic strain value in posterior segment ( Figure 3 , purple arrow) significantly decreased, suggesting deterioration of regional 
DISCUSSION
Fabry disease is an X-linked lysosomal storage disorder caused by deficient activity of the enzyme a-galactosidase A. The cardiac variant of Fabry disease is a relatively prevalent cause of hypertrophic cardiomyopathy and is associated with significant morbidity and early death due to heart failure or ventricular arrhythmias. 3 In the case we present, however, LV function and performance status have remarkably improved. The Tei index, which is reported to be able to detect global LV dysfunction in patients with Fabry disease, 4 also increased during follow-up after CRT (Table 1) . Of course, ablation and optimal medical therapy additionally might improve LV function. As such, we cannot clearly assert the favorable effects of enzyme replacement therapy on myocardial damage, especially in the posterior wall, because the pathologic status had proceeded too far in this case. For confirmation, we have documented the decrease of systolic strain rate value in the posterior wall (Figure 6 ), as Weidemann et al. 5 previously reported strain rate as the primary detector of LV myocardial damage in Fabry disease. This decrease might indicate gradual deterioration of regional myocardial function despite the combination therapy.
To the best of our knowledge, this is the first reported case of Fabry disease with heart failure successfully observed with a long course of combination therapy including CRT. In this rare case, echocardiographic images demonstrated a change for the better in LV dyssynchrony, revealed an improvement in global LV function, and showed a further deterioration of regional myocardial function in the posterior wall, suggesting that even optimal medical therapy may not be able to mitigate all of the pathologic effects of Fabry disease.
CONCLUSIONS
In conclusion, echocardiography was useful for sequential evaluation during treatment for cardiac Fabry disease with heart failure.
SUPPLEMENTARY DATA
Supplementary data related to this article can be found at http://dx. doi.org/10.1016/j.case.2017.04.004. Figure 6 Tissue Doppler radial strain images in the midventricular short-axis view. Before combination therapy (left), systolic strain rate in posterior wall was 0.44 sec À1 (white arrow), suggesting decreased myocardial function. On follow-up after combination therapy (right), it worsened to À0.90 sec À1 (white arrow), suggesting further deterioration of regional contractility.
